First participant dosed with acoramidis in ACT-EARLY, the first ever ATTR primary prevention study – BridgeBio Pharma
BridgeBio Pharma Inc. announced that the first asymptomatic participant with a known pathogenic transthyretin (TTR) variant, that may lead to transthyretin amyloid disease (either cardiomyopathy, ATTR-CM, polyneuropathy, ATTR-PN,… read more.
